Adaptive Biotechnologies Corp (ADPT) - Total Assets
Based on the latest financial reports, Adaptive Biotechnologies Corp (ADPT) holds total assets worth $512.74 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Adaptive Biotechnologies Corp to assess how comfortably operating cash covers total debt obligations.
Adaptive Biotechnologies Corp - Total Assets Trend (2017–2025)
This chart illustrates how Adaptive Biotechnologies Corp's total assets have evolved over time, based on quarterly financial data. See net assets of Adaptive Biotechnologies Corp for net asset value and shareholders' equity analysis.
Adaptive Biotechnologies Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Adaptive Biotechnologies Corp's total assets of $512.74 Million consist of 58.6% current assets and 41.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.8% |
| Accounts Receivable | $50.37 Million | 9.8% |
| Inventory | $9.82 Million | 1.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.73 Million | 0.3% |
| Goodwill | $118.97 Million | 23.2% |
Asset Composition Trend (2017–2025)
This chart illustrates how Adaptive Biotechnologies Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Adaptive Biotechnologies Corp (ADPT) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adaptive Biotechnologies Corp's current assets represent 58.6% of total assets in 2025, an increase from 56.6% in 2017.
- Cash Position: Cash and equivalents constituted 13.8% of total assets in 2025, down from 23.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, a decrease from 36.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 23.2% of total assets.
Adaptive Biotechnologies Corp Competitors by Total Assets
Key competitors of Adaptive Biotechnologies Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Adaptive Biotechnologies Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.34 | 2.89 | 7.16 |
| Quick Ratio | 3.23 | 2.81 | 7.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $210.27 Million | $185.70 Million | $658.19 Million |
Adaptive Biotechnologies Corp - Advanced Valuation Insights
This section examines the relationship between Adaptive Biotechnologies Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.27 |
| Latest Market Cap to Assets Ratio | 4.74 |
| Asset Growth Rate (YoY) | -4.9% |
| Total Assets | $512.74 Million |
| Market Capitalization | $2.43 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Adaptive Biotechnologies Corp's assets at a significant premium (4.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Adaptive Biotechnologies Corp's assets decreased by 4.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Adaptive Biotechnologies Corp (2017–2025)
The table below shows the annual total assets of Adaptive Biotechnologies Corp from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $512.74 Million | -4.94% |
| 2024-12-31 | $539.38 Million | -18.42% |
| 2023-12-31 | $661.13 Million | -22.82% |
| 2022-12-31 | $856.62 Million | -7.23% |
| 2021-12-31 | $923.34 Million | -17.29% |
| 2020-12-31 | $1.12 Billion | +22.37% |
| 2019-12-31 | $912.30 Million | +174.22% |
| 2018-12-31 | $332.69 Million | -8.22% |
| 2017-12-31 | $362.49 Million | -- |
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diag… Read more